Biotechnology company Admit Therapeutics, a member of Catalonia.health, announced its relocation to new, expanded laboratory and office spaces within Almirall’s Innovation Hub "The Hive" at the existing R&D center in Sant Feliu de Llobregat, also a member of Catalonia.health.
This strategic move signifies a key milestone for ADmit Therapeutics, providing access to enhanced infrastructure and fostering even closer collaboration within the scientific ecosystem at "The Hive". The new facilities offer increased capacity and cutting-edge resources to accelerate the company's research and development efforts in the fight against Alzheimer's and other neurodegenerative diseases.
Marta Barrachina, CEO and Co-Founder of ADmit Therapeutics, said: "We are thrilled to establish our new home within 'the Hive'. This relocation not only provides us with superior facilities but also strengthens our ties with a leading pharmaceutical company, creating a synergistic environment that will undoubtedly propel our mission to bring an early diagnostic test for Alzheimer's disease to patients sooner."
Marc Soriano, Executive Director R&D Project, Portofolio and Partner Excellence at Almirall, explained: "Welcoming ADmit to The Almirall Innovation Hub marks a pivotal milestone in our journey towards open collaboration and becoming part of a dynamic science exchange ecosystem, one that fosters industry synergies and strategic partnerships to help transform lives".
Comments